University of Illinois

Purdue Research Foundation

The General Hospital Corporation

Mayo Foundation for Medical Education and Research

Biovitesse, Inc.

Taiwan Semiconductor Manufacturing Comp. Ltd.

Massachusetts Institute of Technology

Vedabio, Inc.

Daktari Diagnostics, Inc.

Labsimply, Inc.

Foxconn Interconnect Technology Limited

Prenosis, Inc.

Rashid Bashir

Anurup Ganguli

Yi-Shao Liu

Jacob Berger

Ashish Pandey

Ariana Mostafa

Bobby Reddy, Jr

Mehmet Toner

Bahadir Erimli

Gerold W Neudeck

Xuanhong Cheng

William Rodriguez

Vincent Chan

Eric M Salm

Laila R Razouk

Dallas Todd Morisette

Rafael Gomez

Nicholas Watkins

Chun-Wen Cheng

Fei-Lung Lai

Michael Ralph Ladisch

Bala Murali Venkatesan

Farhad Kosari

Hyunjoon Kong

Aaron Oppenheimer

Grace Chen

Pinar Zorlutuna

Caroline Cvetkovic

Jaehyun Jeong

Chaenyung Cha

Ritu Raman

Brian T Cunningham

Chun-Yi Chang

Lee Zamir

William P King

Utkan Demirci

Timothy David Sands

Oguz Hasan Elibol

Daniel Irimia

Timothy Scott Fisher

J Paul Robinson

Muhammad Ashraful Alam

Nicholas Peppas

George Vasmatzis

Been-Yang Liaw

Jonghyun Go

Arun K Bhunia

Pradeep R Nair

Matthew Ralph Maschmann

Muhammad Ashraf Alam

Hojeong Yu

Fu Sun

Akid Ornob

Gregory Damhorst

Panagiotis Z Anastasiadis

Enrique Valera

Mehmet Y Aydin

Carlos Eduardo Duarte Guevara

Woo-Jin Chang

Kidong Park

Larry Millet

Lauren Penrose

K Jimmy Hsia

Narayana R Aluru

Weili Chen

Ashraf Alam

Demir Akin

Vikhram Vilasur Swaminathan

Donald E Bergstrom

Liju Yang

Carlos Duarte-Guevara

James Z Hilt

Amit K Gupta

Samuel Wachspress

The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising and a blocking nucleic acid molecule represented by Formula III in the 5′-to-3′ direction comprises: T-D-M-A-(B-L)-C; wherein T is 17-135 nucleotides in length; D is 0-10 nucleotides in length; M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)-C are separate nucleic acid strands; A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D; B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T; L is 3-25 nucleotides in length; J is an integer between 1 and 10; C is 4-15 nucleotides in length; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.

Compositions of matter for detection assays

A microfluidic diagnostic device with a three-dimensional (3D) flow architecture comprises a polymeric body having first and second opposing surfaces and comprising first flow channels in the first opposing surface, second flow channels in the second opposing surface, and connecting flow passages extending through a thickness of the polymeric body to connect the first flow channels to the second flow channels, thereby defining a continuous 3D flow pathway in the polymeric body. The microfluidic diagnostic device also includes a first cover adhered to the first opposing surface to seal the first flow channels, a second cover adhered to the second opposing surface to seal the second flow channels, and one or more access ports in fluid communication with the continuous 3D flow pathway for introducing liquid reagent(s) and/or a sample into the polymeric body.

Microfluidic diagnostic device with a three-dimensional (3D) flow architecture

Provided are methods and related devices for preparing a cell and tissue culture, including a hanging drop culture. Microwells are specially loaded with cell mixtures using a removable reservoir and forcing cells into the underlying microwells. The removable reservoir is removed and the cells partitioned into the individual microwells and covered by an immiscible layer of fluid. The microwells and immiscible layer is inverted and the cells in the microwells cultured. The microwells may have shape-controlling elements to control the three-dimensional shape of the culture.

Microchip high density hanging drop three-dimension culture platform

The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising and a blocking nucleic acid molecule represented by Formula I, wherein Formula I in the 5'-to-3&#x2032; direction comprises: A-(B-L)-C-M-T-D; wherein A is 0-15 nucleotides in length; B is 4-12 nucleotides in length; L is 3-25 nucleotides in length; J is an integer between 1 and 10; C is 4-15 nucleotides in length; M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)-C and T-D are separate nucleic acid strands; T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.

Described herein are systems and methods which utilize an array of wells to isolate pathogens and nucleic acid detection techniques to accurately and rapidly detect pathogens in fluid samples, even in very low concentrations, including from solid or semi-solid samples that have been fluidized. The provided systems and methods dry the fluid sample to deposit a fraction of the total volume in a number of wells and perform nucleic acid detection on individual wells to detect even individual pathogens and provide a quantitative analysis of the amount of pathogen within the sample. Also provided are methods and systems for precise delivery of dried materials, including biomolecules that are enzymes of use in the process, to microwells.

Biomarker detection from fluid samples

Provided herein are methods and devices for characterizing a biomolecule parameter by a nanopore-containing membrane, and also methods for making devices that can be used in the methods and devices provided herein. The nanopore membrane is a multilayer stack of conducting layers and dielectric layers, wherein an embedded conducting layer or conducting layer gates provides well-controlled and measurable electric fields in and around the nanopore through which the biomolecule translocates. In an aspect, the conducting layer is graphene.

Nanopore sensors for biomolecular characterization

Various methods and devices for spatial molecular analysis from tissue is provided. For example, a method of spatially mapping a tissue sample is provided with a microarray having a plurality of wells, wherein adjacent wells are separated by a shearing surface; overlaying said microarray with a tissue sample; applying a deformable substrate to an upper surface of said tissue sample; applying a force to the deformable substrate, thereby forcing underlying tissue sample into the plurality of wells; shearing the tissue sample along the shearing surface into a plurality of tissue sample islands, with each unique tissue sample island positioned in a unique well; and imaging or quantifying said plurality of tissue sample islands, thereby generating a spatial map of said tissue sample. The imaging and/or quantifying may use a nucleic acid amplification technique.

Spatial molecular analysis of tissue

A sample carrier may include a sample preparation module and an amplification module. A sample mixes with a lysis medium and a nucleic acid amplification medium in the sample preparation module and then flows into a plurality of microfluidic chambers in the amplification module. The microfluidic chambers have disposed therein primers configured to initiate amplification of one or more target nucleic acid sequences corresponding to one or more pathogens. The sample carrier is inserted into an apparatus that includes a plurality of Sight sources and a camera. The light sources illuminate the microfluidic chambers with excitation light, a fluorophore emits fluorescence light indicative of nucleic acid amplification in response to the excitation-light, and the camera captures images of the microfluidic chambers. A target nucleic acid sequence in the sample is indicated by the images showing an increasing fluorescence in a microfluidic chamber that has the primers for that sequence.

System for rapid, portable, and multiplexed detection and identification of pathogen specific nucleic acid sequences

A stacked testing assembly () includes a microfluidic cartridge () for analyzing a fluid sample and a testing setup, said microfluidic cartridge includes a number of layers () stacked in a height direction with many different kinds of combinations, said testing setup () is capable of assembling and testing all kinds of said layers combinations with no change to the setup.

Microfluidic cartridge and stacked testing assembly with microfluidic cartridge thereof

The present disclosure provides a biological machine comprising a skeleton comprising at least one hydrogel strip and at least two hydrogel bases, and at least one bioactuator, the at least one bioactuator comprising at least one muscle ring, the muscle ring comprising skeletal muscle cells, wherein the muscle ring is tethered around the at least two pillars. The muscle ring can comprises skeletal muscle, and skeletal muscle innervated with motor neurons, allowing chemical control of muscle contraction. Methods of making the biological machine is also provided.

Muscle-powered biological machines

This disclosure relates to methods and devices to count particles of interest, such as cells. The methods include obtaining a fluid sample that may contain particles of interest; counting all types of particles in a portion of the sample using a first electrical differential counter to generate a first total; removing any particles of interest from the portion of the fluid sample; counting any particles remaining in the portion of the fluid sample using a second electrical differential counter after the particles of interest are removed to generate a second total; and calculating a number of particles of interest originally in the fluid sample by subtracting the second total from the first total, wherein the difference is the number of particles of interest in the sample. These methods and related devices can be used, for example, to produce a robust, inexpensive diagnostic kit for CD4+ T cell counting in whole blood samples.

Counting particles using an electrical differential counter

Provided are methods and devices for the label free detection of analytes in solution, including analytes suspended in a biological fluid. A field effect transistor (FET) is positioned in close proximity to a paired set of reference electrodes and the reference electrodes electrically biased to provide desalting and a stable gate voltage to the FET. In this manner, charged ions are depleted in the sensing region of the sensor and device sensitivity to analyte detection improved by the removal of charge that otherwise interferes with measurement. Also provided are methods and systems providing increased in reference electrode surface area and/or decrease in droplet volume to further improve label-free detection of analytes.

Label free analyte detection by electronic desalting and field effect transistors

Growing community of inventors

Champaign, IL, United States of America

Rashid Bashir